DK0504388T3 - Varicel-zoster-virus-antigen - Google Patents

Varicel-zoster-virus-antigen

Info

Publication number
DK0504388T3
DK0504388T3 DK91919890T DK91919890T DK0504388T3 DK 0504388 T3 DK0504388 T3 DK 0504388T3 DK 91919890 T DK91919890 T DK 91919890T DK 91919890 T DK91919890 T DK 91919890T DK 0504388 T3 DK0504388 T3 DK 0504388T3
Authority
DK
Denmark
Prior art keywords
tgp
secretory
present
vzv
varicella
Prior art date
Application number
DK91919890T
Other languages
English (en)
Inventor
Abbas Vafai
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of DK0504388T3 publication Critical patent/DK0504388T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK91919890T 1990-10-04 1991-10-04 Varicel-zoster-virus-antigen DK0504388T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59276690A 1990-10-04 1990-10-04
PCT/US1991/007280 WO1992006989A1 (en) 1990-10-04 1991-10-04 Varicella-zoster virus antigen

Publications (1)

Publication Number Publication Date
DK0504388T3 true DK0504388T3 (da) 2000-12-27

Family

ID=24371982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91919890T DK0504388T3 (da) 1990-10-04 1991-10-04 Varicel-zoster-virus-antigen

Country Status (10)

Country Link
US (1) US6180369B1 (da)
EP (1) EP0504388B1 (da)
JP (1) JP3990445B2 (da)
KR (1) KR920703614A (da)
AT (1) ATE196163T1 (da)
CA (1) CA2068654C (da)
DE (1) DE69132404T2 (da)
DK (1) DK0504388T3 (da)
ES (1) ES2150906T3 (da)
WO (1) WO1992006989A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4562812B2 (ja) 1992-07-17 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法
GB9413751D0 (en) * 1994-07-07 1994-08-24 British Bio Technology Immunodominant peptides
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
US6528066B1 (en) * 1999-09-14 2003-03-04 University Of Iowa Research Foundation Variant varicella-zoster viruses and methods of use
WO2019225962A1 (ko) * 2018-05-23 2019-11-28 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도
CN112941031B (zh) * 2021-02-20 2023-06-27 安徽智飞龙科马生物制药有限公司 一种gE-HEK293细胞的构建方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008317A (en) 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
DE2930706A1 (de) 1979-07-28 1981-02-05 Medac Klinische Spezialpraep Verfahren zum nachweis von erregerspezifischen antikoerpern
US4663277A (en) 1983-05-20 1987-05-05 Profile Diagnostic Sciences Inc. Virus detection method and materials
EP0628633B1 (en) 1984-04-06 2003-01-08 Chiron Corporation Recombinant herpes simplex gB-gD vaccine
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4686101A (en) 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
JPH01252279A (ja) 1988-03-31 1989-10-06 Chemo Sero Therapeut Res Inst 帯状疱疹ウイルス糖蛋白質およびその製法
ES2071770T3 (es) 1989-06-27 1995-07-01 Smithkline Beecham Biolog Nuevos compuestos.
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
JPH03232897A (ja) * 1989-11-16 1991-10-16 Takeda Chem Ind Ltd ポリペプチドおよびその製造法
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
NL9100989A (nl) * 1991-06-07 1993-01-04 Stichting Centr Diergeneeskund Bovine herpesvirus type 1 deletiemutanten, daarop gebaseerde vaccins, diagnostische kits voor detectie van bovine herpesvirus type 1.

Also Published As

Publication number Publication date
ES2150906T3 (es) 2000-12-16
ATE196163T1 (de) 2000-09-15
EP0504388B1 (en) 2000-09-06
EP0504388A4 (en) 1993-04-28
WO1992006989A1 (en) 1992-04-30
JP3990445B2 (ja) 2007-10-10
DE69132404D1 (de) 2000-10-12
JPH05502595A (ja) 1993-05-13
US6180369B1 (en) 2001-01-30
CA2068654C (en) 2011-01-04
EP0504388A1 (en) 1992-09-23
DE69132404T2 (de) 2001-02-15
CA2068654A1 (en) 1992-04-05
KR920703614A (ko) 1992-12-18

Similar Documents

Publication Publication Date Title
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
DE3876496D1 (de) Synthetisches peptid-antigen fuer nachweis von hiv-2-infektionen.
KR900700507A (ko) Htlv-1 감염 검출용 합성 펩티드 항원
PT649537E (pt) Imunoanalises para anticorpos anti-vhc utilizando antigenios com epitopos conformacionais
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
ATE172542T1 (de) Vergrössertes western blot format und ein immunotestverfahren für die bestimmung von viralen antikörpern
GB2154609B (en) Hcmv monoclonal antibodies and their use in the detection of hcmv infection and hcmv specific igm, and methods of detecting viral antigens
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
IT1266740B1 (it) Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
ATE71141T1 (de) Diagnosesystem zum nachweis von cytomegalovirus.
DK0504388T3 (da) Varicel-zoster-virus-antigen
DK187286A (da) Herpes-virus-specifikke immunologiske materialer og metoder
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
WO1993017110A3 (en) A recombinant hepatitis c virus polypeptide
Li et al. Expression of Epstein‐Barr‐virus‐related nuclear antigens and B‐cell markers in lymphomas of SIV‐immunosuppressed monkeys
Horsfall et al. Purification of human autoantibodies from cross-linked antigen immunosorbents
Franti et al. Immune reactivity of human sera to the glycoprotein B of human herpesvirus 7
Cammack et al. Antigenic analysis of yellow fever virus glycoproteins: use of monoclonal antibodies in enzyme-linked immunosorbent assays
DE68925202D1 (de) HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke
EP0687308A4 (en) RECOMBINANT CAPSIDANTIGENT OF THE EPSTEIN-BARR VIRUSES, WHICH IS USEFUL IN A DIAGNOSTIC METHOD
Garzelli et al. Epstein-Barr Virus-Induced Autoimmunity through Anti-Idiotype Studies
Oba Epstein-Barr virus glycoprotein gp85: Biochemical characteristics, purification and mapping to viral genome.
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.